Scholar Rock (NASDAQ:SRRK) Director Jeffrey Flier Sells 3,053 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey Flier sold 3,053 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total value of $164,495.64. Following the sale, the director owned 27,856 shares of the company’s stock, valued at $1,500,881.28. This represents a 9.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Up 0.9%

NASDAQ SRRK traded up $0.48 during mid-day trading on Monday, reaching $55.36. 1,182,357 shares of the company’s stock traded hands, compared to its average volume of 1,407,918. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. Scholar Rock Holding Corporation has a 1-year low of $27.07 and a 1-year high of $56.54. The company has a fifty day simple moving average of $48.43 and a 200-day simple moving average of $46.59. The company has a market cap of $6.63 billion, a price-to-earnings ratio of -15.42 and a beta of 0.67.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the prior year, the firm posted ($0.67) earnings per share. As a group, equities research analysts expect that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SRRK. IFP Advisors Inc raised its stake in Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Scholar Rock in the 4th quarter worth $30,000. Summit Securities Group LLC bought a new position in shares of Scholar Rock during the 4th quarter worth about $31,000. Ramirez Asset Management Inc. acquired a new position in shares of Scholar Rock during the third quarter valued at about $37,000. Finally, EverSource Wealth Advisors LLC raised its position in shares of Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares during the last quarter. 91.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

SRRK has been the subject of a number of recent research reports. Canaccord Genuity Group started coverage on shares of Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 price objective for the company. Barclays raised their price objective on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. JPMorgan Chase & Co. boosted their price target on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, March 16th. HC Wainwright increased their price objective on Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, Wedbush upped their price target on shares of Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a research report on Wednesday, April 1st. Four investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $56.00.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).